[New treatments for impotence].
The development of new oral drugs and the poor results of the reconstructive vascular surgery has modified the therapeutical approach of the impotent patient. The doctor has to be aware of these changes in the management of impotence.
Wespes
E
E
Service d'Urologie, C.H.U. de Charleroi.
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000284:Administration, Oral; D000075202:Contraindications; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D018783:Impotence, Vasculogenic / Q000188:drug therapy / Q000601:surgery / Q000628:therapy; D007267:Injections; D008297:Male; D019935:Penile Implantation; D010413:Penis; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases